Details
Stereochemistry | RACEMIC |
Molecular Formula | C8H10FN3O3S |
Molecular Weight | 247.247 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)N(C=C1F)[C@@H]2CS[C@H](CO)O2
InChI
InChIKey=XQSPYNMVSIKCOC-NTSWFWBYSA-N
InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1
DescriptionCurator's Comment: Description was created based on several sources, including:
http://www.emory.edu/news/Releases/emtri/
Curator's Comment: Description was created based on several sources, including:
http://www.emory.edu/news/Releases/emtri/
Emtricitabine was discovered by Emory researchers Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi and Dr. Woo-Baeg Choi and licensed to Triangle Pharmaceuticals by Emory University in 1996. Triangle was acquired by Gilead in 2003. Emtricitabine, marketed by Gilead as Emtriva, was first approved by the U.S. Food and Drug Administration in July 2003 for the treatment of HIV infection in combination with other antiretroviral agents. Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination.
CNS Activity
Originator
Sources: http://www.emory.edu/news/Releases/emtri/
Curator's Comment: Liotta, Schinazi and Choi (Emory University) and licensed to Triangle Pharmaceuticals by Emory University in 1996
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL247 |
0.31 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | EMTRIVA Approved UseEMTRIVA is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection. Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection:
• EMTRIVA should not be coadministered with ATRIPLA™, TRUVADA®, or Lamivudine-containing products (see WARNINGS).
• In treatment-experienced patients, the use of EMTRIVA should be guided by laboratory testing and treatment history (see MICROBIOLOGY). Launch Date2003 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.8 μg/mL |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EMTRICITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.7 μg/mL |
5.6 mg/kg 1 times / day steady-state, oral dose: 5.6 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
EMTRICITABINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 μg × h/mL |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EMTRICITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
12.6 μg × h/mL |
5.6 mg/kg 1 times / day steady-state, oral dose: 5.6 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
EMTRICITABINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 h |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EMTRICITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.2 h |
5.6 mg/kg 1 times / day steady-state, oral dose: 5.6 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
EMTRICITABINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
96% |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EMTRICITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: dolutegravir(50 mg) Sources: tenofovir disoproxil fumarate(300 mg) |
unhealthy, 26 - 42 years n = 717 Health Status: unhealthy Condition: HIV-1 Age Group: 26 - 42 years Sex: M+F Population Size: 717 Sources: |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (grade 2-5, 8 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | grade 2-5, 8 patients Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: dolutegravir(50 mg) Sources: tenofovir disoproxil fumarate(300 mg) |
unhealthy, 26 - 42 years n = 717 Health Status: unhealthy Condition: HIV-1 Age Group: 26 - 42 years Sex: M+F Population Size: 717 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. | 2000 Jun |
|
Antiviral beta-L-nucleosides specific for hepatitis B virus infection. | 2001 |
|
Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. | 2001 Jun |
|
Gateways to clinical trials. | 2002 Dec |
|
Management of viral hepatitis B. | 2002 Feb |
|
[New management strategies for hepatitis B]. | 2002 Feb |
|
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. | 2002 Jun |
|
Gateways to clinical trials. | 2002 Nov |
|
Therapy of chronic hepatitis B: current challenges and opportunities. | 2002 Nov |
|
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. | 2003 Dec |
|
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. | 2003 Dec 15 |
|
Gateways to clinical trials. | 2003 Jan-Feb |
|
Reproductive toxicology profile of emtricitabine in mice and rabbits. | 2003 Jan-Feb |
|
Gateways to clinical trials. | 2003 Jul-Aug |
|
Gateways to clinical trials. March 2003. | 2003 Mar |
|
Current and future antiviral agents for chronic hepatitis B. | 2003 Mar |
|
FDA notifications. NRTI Emtriva receives FDA approval. | 2003 Oct |
|
Emtricitabine/tenofovir disoproxil fumarate. | 2004 |
|
New once-daily HIV combination better tolerated. | 2004 Dec |
|
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. | 2004 Jan |
|
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. | 2004 Jul 14 |
|
New drugs of 2003. | 2004 Mar-Apr |
|
Emtricitabine (FTC) for the treatment of HIV infection. | 2004 May |
|
Pharmacologic perspectives for once-daily antiretroviral therapy. | 2004 Nov |
|
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. | 2004 Oct |
|
Resistance issues with new nucleoside/nucleotide backbone options. | 2004 Sep 1 |
|
New nucleoside/nucleotide backbone options: a review of recent studies. | 2004 Sep 1 |
|
Intracellular pharmacology of emtricitabine and tenofovir. | 2004 Sep 15 |
Sample Use Guides
Emtriva® (emtricitabine) dosage.
Adult Patients (18 years of age and older):one 200 mg capsule administered once daily orally (Capsules). 240 mg (24 mL) administered once daily orally (Oral Solution).
Pediatric Patients (0–3 months of age): 3 mg/kg administered once daily orally (Oral Solution).
Pediatric Patients (3 months through 17 years): 6 mg/kg up to a maximum of 240 mg (24 mL) administered once daily orally (Oral Solution), for children weighing more than 33 kg who can swallow an intact capsule, one 200 mg capsule administered once daily orally (Capsules).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23187937
emtricitabine EC50 0.99 μM (in vitro activity against HIV-2)
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12753
Created by
admin on Sat Dec 16 06:50:02 GMT 2023 , Edited by admin on Sat Dec 16 06:50:02 GMT 2023
|
PRIMARY | |||
|
143491-54-7
Created by
admin on Sat Dec 16 06:50:02 GMT 2023 , Edited by admin on Sat Dec 16 06:50:02 GMT 2023
|
PRIMARY | |||
|
ULS8902U4O
Created by
admin on Sat Dec 16 06:50:02 GMT 2023 , Edited by admin on Sat Dec 16 06:50:02 GMT 2023
|
PRIMARY | |||
|
60877
Created by
admin on Sat Dec 16 06:50:02 GMT 2023 , Edited by admin on Sat Dec 16 06:50:02 GMT 2023
|
PRIMARY | |||
|
C075889
Created by
admin on Sat Dec 16 06:50:02 GMT 2023 , Edited by admin on Sat Dec 16 06:50:02 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD